Otezla (apremilast) is a brand-name oral tablet that’s prescribed for conditions such as psoriatic arthritis. The drug’s cost with and without insurance can depend on several factors, such as whether ...

Please provide your email address to receive an email when new articles are posted on . According to the psoriatic arthritis MRI score, Otezla decreased inflammation 2.32 points from baseline. Otezla ...

(Reuters) - Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion (£10.9 billion) in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Apremilast 75mg; ext-rel tabs. Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased ...

Please provide your email address to receive an email when new articles are posted on . Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis.

The surprise bill exposed how insurance rules can still leave Americans paying for costly prescriptions.

Otezla is used to treat plaque psoriasis for whom phototherapy or systemic therapy is appropriate; active psoriatic arthritis; and oral ulcers associated with Behçet’s Disease. Glenmark has received ...

PHILADELPHIA (CBS) -- A drug used to treat a common skin condition can also help people lose weight and reduce the risk of heart disease, new research from the University of Pennsylvania shows. Kim ...

Amgen shared that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz ...

Amgen AMGN announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a district court’s decision in a patent litigation case related to blockbuster psoriasis therapy Otezla ...